OnKure Therapeutics
OKUR
75 hedge funds and large institutions have $159M invested in OnKure Therapeutics in 2026 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 21 increasing their positions, 9 reducing their positions, and 8 closing their positions.
300% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 8
133% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 9
47% more funds holding
Funds holding: 51 → 75 (+24)
40% more capital invested
Capital invested by funds: $114M → $159M (+$45.1M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
114.96% less ownership
Funds ownership: 201.27% → 86.31% (-115%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.22M |
| 2 |
TECP
Trails Edge Capital Partners
Atlanta,
Georgia
|
+$6.17M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$5.39M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$4.93M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
+$4.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMV
Foresite Capital Management VI
Larkspur,
California
|
-$5.99M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
-$5.04M |
| 3 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$1.26M |
| 4 |
DT
DV Trading
Chicago,
Illinois
|
-$998K |
| 5 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$842K |
OKUR Hedge Fund Activity: Q2 2026 in Review
75 of the 8,316 institutional investors tracked by Wall St. Rank reported a position in OnKure Therapeutics (OKUR) for Q2 2026, worth a combined $159M — up 40% from $114M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new OKUR positions and 8 closed out — a net gain of 24 holders — while 21 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock, adding an estimated $6.22M. The largest seller was Foresite Capital Management VI, exiting entirely with an estimated $5.99M sold.
- 75 institutional investors held OnKure Therapeutics (OKUR) as of Q2 2026, up from 51 in Q1 2026.
- Funds reported $159M of OnKure Therapeutics stock for Q2 2026, up 40% quarter-over-quarter.
- 32 funds opened new OnKure Therapeutics positions in Q2 2026 and 8 closed out, a net change of +24 holders.
- The largest OnKure Therapeutics buyer in Q2 2026 was BlackRock, an estimated $6.22M added.
- The largest OnKure Therapeutics seller in Q2 2026 was Foresite Capital Management VI, an estimated $5.99M sold.
Based on aggregated 13F filings for Q2 2026.